SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users fiercely debate the administration's military strategy in the Strait of Hormuz, with community discussion highlighting friction over requests for allied support following recent escalations. The conversation is heavily polarized, featuring widespread speculation on potential economic fallout and criticism regarding the lack of a clear long-term geopolitical plan.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending following a GTC keynote where CEO Jensen Huang projected over $1 trillion in AI infrastructure demand through 2027, signaling massive long-term growth for the company's Blackwell and Vera Rubin platforms. While the announcement fueled initial volatility and intense debate among investors over the stock's valuation and the reality of meeting such high revenue targets, the community remains divided between those viewing the pullback as a buying opportunity and others skeptical of the company's ability to sustain its premium market position.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant traction as a critical infrastructure provider in the DeFi sector, driven by its recent integration of institutional-grade financial data and its unique position in supplying macroeconomic indicators to blockchain ecosystems. Community members are actively highlighting the project's institutional backing, revenue-sharing model through token buybacks, and its role as a core player in the emerging Real World Asset (RWA) narrative.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as community members weigh the impact of the ASI merger and partnership integrations against a prolonged period of price volatility and FUD. While some investors are aggressively accumulating during the downturn, citing the project's long-term utility in the agentic AI sector, others remain skeptical, focusing on recent token supply dynamics and the broader underperformance of altcoins.

Electro Optic Systems Holdings Ltd. develops and produces products incorporating advanced electro-optic technologies for the aerospace market. It operates through the Space Systems and Defence Systems segments. The Space Systems segment is involved in ground products available to support the Australian and international space markets. The Defence Systems segment develops, manufactures, and markets advanced fire control, surveillance, and weapon systems to approved military customers. The company was founded by Benny Allan Greene in 1983 and is headquartered in Symonston, Australia.

Electro Optic Systems Holdings Ltd

Electro Optic Systems is gaining significant community attention as it secures multiple defense contracts for its counter-drone and laser weapon technologies, with investors highlighting the company's expanding backlog and strong performance in comparative military trials. The ongoing global demand for advanced, cost-effective air defense systems is driving discussions around the firm's strategic growth, international partnerships, and potential for increased market presence.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Ripple (XRP) is experiencing high volatility as investors debate the legitimacy of recent price movements, with sentiment split between optimism over potential institutional adoption and skepticism regarding recurring sell-offs. The community remains deeply divided, with many actively trading around short-term price fluctuations while others hold long-term positions, waiting for clarity on regulatory milestones and market decoupling from Bitcoin.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community reacts to NOAA determining that the company's consolidated deep-sea mining application for the Clarion-Clipperton Zone is in substantial compliance, a regulatory milestone that paves the way for further review. Investors are actively discussing the implications of this expansion and the company's positioning alongside upcoming corporate developments, with many highlighting the stock as a critical play for domestic mineral security.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing intense market attention and a surge in trading volume driven by unconfirmed takeover rumors involving a large U.S.-based biopharmaceutical company. Investors are actively debating the potential for an M&A exit, comparing current valuations to historical biotech acquisition multiples while weighing the credibility of these reports against the company's established commercial growth.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is seeing a surge in sentiment driven by its growing enterprise utility, specifically high-profile integrations like the collaboration with FedEx that highlights the network's potential for massive transaction volume. While the broader market remains volatile, the community is focused on the project's long-term scalability and the potential regulatory tailwinds from the Clarity Act, fueling ongoing debate between those accumulating at these levels and those frustrated by historical price dilution.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently facing intense volatility and downward pressure as investors closely monitor its pre-revenue status and the heavy insider selling that has tempered the enthusiasm from earlier retail rallies. The community remains deeply divided, with bulls pointing to the company's long-term potential as a critical power source for AI data centers and government-backed nuclear initiatives, while skeptics emphasize the significant regulatory hurdles, project timelines, and the lack of current earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Sarepta is looking to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</li><li>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li><li>While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</li></ul>Shares of Sarepta Therapeutics, Inc. (SRPT) edged up nearly 1.5% on Monday after the company said that screening and enrollment are underway in a cohort of its study, aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.Data from the cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks of acute liver injury and acute liver failure associated with Elevidys in DMD patients who cannot walk.<h2 class="st-heading-2">Gene Therapy Study Details</h2>Sarepta is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-screening-and-enrollment-are-underway-endeavor">looking</a> to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.Patients enrolled in the cohort will be administered peri-infusion sirolimus 14 days before Elevidys administration and will continue to receive it for 12 weeks after Elevidys, the company said.Elevidys is the only approved gene therapy for Duchenne, a severe, progressive genetic muscle-wasting disease, primarily affecting young boys.Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.<h2 class="st-heading-2">Street Consensus</h2>Last week, Mizuho raised the firm's price target on Sarepta to $31 from $26 and kept an ‘Outperform’ rating on the shares, while Citi raised the its price target on Sarepta to $9 from $8 and kept a ‘Sell’ rating on the shares.According to data from Koyfin, the average 12-month price target on the stock is $20.61, representing a potential upside of about 24% from current trading levels, as of the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has fallen nearly 84% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-halts-v3-supercharger-production-in-new-york/cZ3PEpcRIQb">Tesla Halts V3 Supercharger Production In New York In Favor Of Faster, Rival EV-Compatible Variant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 

Equity

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 


Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

<ul class="summary-bullets"><li>The company also secured a private placement financing worth around $200 million.</li><li>Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR.</li><li>Remaining funds will be used for the development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.</li></ul>Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.<a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> rose to its highest since May 2024 and recorded its biggest-ever intraday gains. Trading in the stock was twice halted after the opening bell, according to Nasdaq data.The acquisition adds Faeth’s lead investigational therapy, PIKTOR, an all-oral drug combination that targets tumor metabolism and blocks multiple points in the PI3K/AKT/mTOR pathway, a critical cell signaling system that regulates cell survival, growth, and division.“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and the new COO and director of Sensei.<h2 class="st-heading-2">$200 Million Private Placement</h2>Sensei Biotherapeutics also secured private placement financing, worth about $200 million. The company plans to use most of the capital to advance PIKTOR, including topline results from an ongoing Phase 2 trial in second-line advanced endometrial cancer and the launch of a Phase 1b study in HR+/HER2- advanced breast cancer, both anticipated by the end of 2026.Remaining funds will support general corporate initiatives and the continued development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.The private placement attracted participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, and Vivo Capital, among other life sciences funds and institutional investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish,’ amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SNSE_jpg_53f7157d12.webp" alt="SNSE.jpg">One user expects the stock to “go up big” if it holds above the $25.4 to $25.5 support. It is currently trading at around $28.<stembedurl>https://stocktwits.com/brewstocks123/message/645236001</stembedurl>Another user expects the stock to climb to $44 by the end of the session.<stembedurl>https://stocktwits.com/FreyBentos/message/645238839</stembedurl>The stock has gained around 160% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rxt-stock-soars-pre-market-palantir-connection/cZR0r6BR4vX">RXT Stock Soared 275% Today – What’s The Connection&nbsp;With Palantir?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Representative image of a trending stock chart.

 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

<ul class="summary-bullets"><li>The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group.</li><li>ELEVIDYS reduced the rate of functional decline by about 70%.</li><li>ELEVIDYS has been administered to more than 1,200 patients worldwide in both clinical trials and real-world use.</li></ul>Shares of Sarepta Therapeutics (SRPT) jumped 6% in pre-market trading on Monday after the company announced positive three-year topline results from its Phase 3 EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with Duchenne Muscular Dystrophy (DMD).SRPT shares gained further after the opening bell, trading 12% higher at the time of writing.The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group. Three years after treatment, patients maintained North Star Ambulatory Assessment (NSAA) scores above baseline, while untreated patients showed the expected decline.ELEVIDYS reduced the rate of functional decline by about 70% or more on key measures, including Time to Rise and the 10-meter walk/run, with the treatment effect increasing over time. No new safety concerns were identified, supporting ELEVIDYS’ manageable safety profile.Sarepta said analysis of its three-year data is ongoing and includes functional results from patients who crossed over to treatment and have now been followed for two years.&nbsp;ELEVIDYS is currently the only approved gene therapy for DMD and has been given to more than 1,200 patients worldwide in both clinical trials and real-world use. The therapy is available for ambulatory patients aged four and older under an updated FDA label announced in late 2025.&nbsp;<h2 class="st-heading-2">Latest Updates</h2>Sarepta is working with Roche to broaden global access to the therapy, with Sarepta handling U.S. regulatory approval, manufacturing, and commercialization, and Roche managing approvals and distribution outside the United States.Earlier this month, the company announced the submission of a clinical trial application to New Zealand’s Medsafe for its INSIGHTT study of SRP-1005, an investigational small interfering RNA (siRNA) therapy for Huntington’s disease. If approved, the first-in-human trial is expected to begin in the second quarter of 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/srpt_jpg_4e3ede4352.webp" alt="srpt.jpg">One bullish user said the ‘results are very impressive for a rare disease with no cure’.<stembedurl>https://stocktwits.com/free2dream/message/642864936</stembedurl>Another user added that breaking the $25 resistance mark would be huge. The stock is currently trading around $23.5.<stembedurl>https://stocktwits.com/Sareptaking/message/642878594</stembedurl>The stock has been under heavy selling pressure over the past year, declining more than 80%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/traw-stock-slides-in-volatile-session-after-covid-19-treatment-trial-update/cmy7u2BR4hI">TRAW Stock Slides In Volatile Session –&nbsp; What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did SRPT Stock Rise 6% In Pre-Market Today?

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.   

SRPT Pre-Market Rally Fueled By Promising DMD Therapy Results

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.

 

<ul class="summary-bullets"><li>Shiong added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors.</li><li>Explaining what this means, he said that half of the patients at this stage do not survive beyond six months.</li><li>The Culver City, California-based immunotherapy company stated in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial.</li></ul>ImmunityBio Inc. (IBRX) shares were up more than 5% in Monday’s pre-market trade after a volatile session on Friday following the company’s Phase 2 glioblastoma trial update.The Culver City, California-based immunotherapy company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-volatility-after-immunitybio-phase-2-glioblastoma-trial-update/cmyR7VnR4gk">stated</a> in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial. The company said that as of Jan. 22, 2026, it had enrolled 23 patients in the Phase 2 glioblastoma trial, of which four deaths have been reported so far, while 14 patients have evaluable clinical data.<h2 class="st-heading-2">ImmunityBio Founder Issues Clarification</h2>However, Patrick Soon Shiong, ImmunityBio’s founder,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2015148449059201385">took</a> to X on Saturday to clarify what the update signified.“The fact that we have patients alive still at 12 months and that the ‘median has NOT YET&nbsp; been reached’ IS a positive and promising finding to date with our chemo free treatment in which patients have failed current standards of care,” he said.He added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors. Explaining what this means, he said that half of the patients at this stage do not survive beyond the timeframe of six months or longer.<figure class="image"><img src="https://news.stocktwits-cdn.com/Patrick_post_jpg_65b0607bff.webp" alt="Dr. Pat Soon-Shiong's post on X" width="727" height="500"><figcaption>Dr. Pat Soon-Shiong's post on X | @DrPatrick/X</figcaption></figure><h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio</a> was in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user said that they believe IBRX should trade at a market capitalization of $10 billion, while adding that ImmunityBio represents a “complete shift in standard of care of cancer.” The company’s current market capitalization is $6.35 billion.<stembedurl>https://stocktwits.com/BixbyKnolls/message/642850960</stembedurl>Another user wondered why any investor would not hold the IBRX stock with “so many approvals on the horizon.”<stembedurl>https://stocktwits.com/Nate711/message/642846497</stembedurl><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is up 226% year-to-date and 107% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-silver-gold-price-rally-people-clueless-slv-gld-etf-soar-pre-market/cmy7FWpR4Wx">Peter Schiff Says Most People Are 'Clueless' And In For A 'Shock' As Gold, Silver Scale New Highs: SLV, GLD ETFs Soar Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



FBT
First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FBT News

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund